GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY24 results · Apr–Jun 2023
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹761.66 crore (up 2.2% from Q1 FY23) and net profit of ₹132.25 crore (up 10.9% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 761.66 | 745.10 | +2.2% | 787.45 | −3.3% |
| Other income | 36.44 | 27.61 | +32.0% | 27.66 | +31.7% |
| Total income | 798.10 | 772.71 | +3.3% | 815.11 | −2.1% |
| Profit before tax | 180.98 | 160.03 | +13.1% | 189.97 | −4.7% |
| Net profit for the period | 132.25 | 119.28 | +10.9% | 133.43 | −0.9% |
| EPS, basic (₹) | 7.04 | 7.04 | +0.0% | 7.88 | −10.7% |
| Net margin (%) | 17.4 | 16.0 | 16.9 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 738.02 | 729.46 | +1.2% | 782.16 | −5.6% |
| Other income | 36.80 | 27.79 | +32.4% | 27.97 | +31.6% |
| Total income | 774.82 | 757.25 | +2.3% | 810.13 | −4.4% |
| Profit before tax | 178.71 | 159.22 | +12.2% | 187.30 | −4.6% |
| Net profit for the period | 130.58 | 118.68 | +10.0% | 131.48 | −0.7% |
| EPS, basic (₹) | 6.94 | 7.01 | −1.0% | 7.77 | −10.7% |
| Net margin (%) | 17.7 | 16.3 | 16.8 |
Consolidated
- Filed with BSE
- 27 Jul 2023, 12:50 IST
- Board meeting
- 26 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2023, 12:50 IST
- Board meeting
- 26 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE